- Home
- NUW vs CVRX Comparison
NUW vs CVRX Comparison
Compare NUW & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUW
- CVRX
- Stock Information
- Founded
- NUW 2008
- CVRX 2000
- Country
- NUW United States
- CVRX United States
- Employees
- NUW N/A
- CVRX N/A
- Industry
- NUW Investment Managers
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NUW Finance
- CVRX Health Care
- Exchange
- NUW Nasdaq
- CVRX Nasdaq
- Market Cap
- NUW 246.8M
- CVRX 203.9M
- IPO Year
- NUW N/A
- CVRX 2021
- Fundamental
- Price
- NUW $14.08
- CVRX $6.92
- Analyst Decision
- NUW
- CVRX Buy
- Analyst Count
- NUW 0
- CVRX 7
- Target Price
- NUW N/A
- CVRX $14.00
- AVG Volume (30 Days)
- NUW 45.3K
- CVRX 178.7K
- Earning Date
- NUW 01-01-0001
- CVRX 10-28-2025
- Dividend Yield
- NUW 3.66%
- CVRX N/A
- EPS Growth
- NUW N/A
- CVRX N/A
- EPS
- NUW N/A
- CVRX N/A
- Revenue
- NUW N/A
- CVRX $54,652,000.00
- Revenue This Year
- NUW N/A
- CVRX $11.32
- Revenue Next Year
- NUW N/A
- CVRX $18.58
- P/E Ratio
- NUW N/A
- CVRX N/A
- Revenue Growth
- NUW N/A
- CVRX 23.11
- 52 Week Low
- NUW $12.45
- CVRX $4.30
- 52 Week High
- NUW $14.44
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- NUW 70.78
- CVRX 39.52
- Support Level
- NUW $14.03
- CVRX $7.22
- Resistance Level
- NUW $14.15
- CVRX $8.35
- Average True Range (ATR)
- NUW 0.10
- CVRX 0.43
- MACD
- NUW 0.04
- CVRX -0.05
- Stochastic Oscillator
- NUW 86.54
- CVRX 3.38
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.